G1 THERAPEUTICS (NASDAQ:GTHX) major shareholder Medimmune Ventures, Inc. sold 133,906 shares of G1 THERAPEUTICS stock in a transaction on Friday, December 1st. The stock was sold at an average price of $19.75, for a total transaction of $2,644,643.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Medimmune Ventures, Inc. also recently made the following trade(s):
- On Monday, November 20th, Medimmune Ventures, Inc. sold 200,000 shares of G1 THERAPEUTICS stock. The stock was sold at an average price of $20.01, for a total transaction of $4,002,000.00.
Shares of G1 THERAPEUTICS (GTHX) traded up $0.07 during midday trading on Wednesday, hitting $19.08. 83,100 shares of the company traded hands, compared to its average volume of 99,367. G1 THERAPEUTICS has a one year low of $12.04 and a one year high of $28.67.
Large investors have recently bought and sold shares of the stock. RA Capital Management LLC bought a new stake in G1 THERAPEUTICS during the second quarter worth about $46,813,000. Laurion Capital Management LP bought a new stake in G1 THERAPEUTICS during the second quarter worth about $3,488,000. Goldman Sachs Group Inc. bought a new position in shares of G1 THERAPEUTICS in the second quarter worth approximately $1,144,000. FMR LLC bought a new position in shares of G1 THERAPEUTICS in the second quarter worth approximately $34,093,000. Finally, Victory Capital Management Inc. bought a new position in shares of G1 THERAPEUTICS in the second quarter worth approximately $889,000. 43.25% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “G1 THERAPEUTICS (GTHX) Major Shareholder Medimmune Ventures, Inc. Sells 133,906 Shares” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://stocknewstimes.com/2017/12/06/g1-therapeutics-gthx-major-shareholder-medimmune-ventures-inc-sells-133906-shares.html.
G1 THERAPEUTICS Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.